Bladder Cancer Risk Stratification: Moving from the Old to the New
Joshua J. Meeks, MD, PhD, discusses risk stratification and treatment options for patients with non-muscle-invasive bladder cancer (NMIBC).
Read More
2022
Modalities, Maps and Margins: Optimizing Oncologic Efficacy
Mark Emberton, MD, FRCS, discusses current technologies and modern lesion management strategies for destroying prostate cancer cells.
Read More
Alternative Payment Models: Value Care Bundling
Cary (C.J.) Stimson, MD, JD, discusses the potential of value care bundling to improve the healthcare landscape.
Read More
Need to Know: Experience with Lutetium (Pluvicto) for Prostate Cancer Theranostics
E. David Crawford, MD, interviews Edwin M. Posadas, MD, FACP, on his clinical experience with lutetium.
Read More
Management of Refractory OAB Patient: Insights from a 20-year Experience Using Advanced OAB Techniques
Christopher P. Smith, MD, MBA, MSS, discusses management of overactive bladder (OAB), drawing on 20 years of clinical experience.
Read More